PDF herunterladen
Semin Respir Crit Care Med 2017; 38(04): 450-462
DOI: 10.1055/s-0037-1603767
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Sarcoidosis-Associated Pulmonary Hypertension

Oksana A. Shlobin
1   Pulmonary Vascular Disease Program, Inova Fairfax Hospital, Falls Church, Virginia
,
Robert P. Baughman
2   Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Juli 2017 (online)

    Lizenzen und Reprints

Abstract

Sarcoidosis-associated pulmonary hypertension (SAPH) is found in 5 to 20% of sarcoidosis patients. Elevated pulmonary artery pressure may be due to multiple factors, including vasculocentric, parenchymal, and mechanical, as well as comorbidities such as cardiac sarcoidosis and sleep apnea. Most SAPH patients have fibrotic lung disease, but SAPH may be present in those without advanced parenchymal lung disease. Several features have been shown to suggest SAPH, including reduced DLCO, shortened 6-minute walk distance, with or without desaturation, and the presence of increased pulmonary artery to aorta ratio on CT scanning. Echocardiography remains an important tool for the evaluation of SAPH but may both over- or underestimate the severity of pulmonary artery pressure. Right heart catheterization remains the definitive test to make the diagnosis. There have been several reports on the value of different modalities of treating SAPH. These include prospective clinical trials and one double-blind placebo-controlled randomized trial. Evidence-based guidelines for treatment of SAPH are discussed in this review.

Keywords

precapillary pulmonary hypertension - bosentan - epoprostenol - echocardiography - right heart catheterization
 

  • References

  • 1 Handa T, Nagai S, Miki S. , et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129 (05) 1246-1252
    CrossrefPubMedGoogle Scholar
  • 2 Keir GJ, Walsh SL, Gatzoulis MA. , et al. Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (02) 82-90
    PubMedGoogle Scholar
  • 3 Alhamad EH, Idrees MM, Alanezi MO, Alboukai AA, Shaik SA. Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients. Ann Thorac Med 2010; 5 (02) 86-91
    CrossrefPubMedGoogle Scholar
  • 4 Głuskowski J, Hawryłkiewicz I, Zych D, Wojtczak A, Zieliński J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 5 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (02) 296-302
    CrossrefPubMedGoogle Scholar
  • 6 Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25 (05) 783-788
    CrossrefPubMedGoogle Scholar
  • 7 Baughman RP, Field S, Costabel U. , et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 2016; 13 (08) 1244-1252
    CrossrefPubMedGoogle Scholar
  • 8 Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138 (05) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 9 Patel MB, Mor-Avi V, Murtagh G. , et al. Right heart involvement in patients with sarcoidosis. Echocardiography 2016; 33 (05) 734-741
    CrossrefPubMedGoogle Scholar
  • 10 Iwai K, Sekiguti M, Hosoda Y. , et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11 (01) 26-31
    PubMedGoogle Scholar
  • 11 Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Cardiac sarcoidosis. Clin Chest Med 2015; 36 (04) 657-668
    PubMedGoogle Scholar
  • 12 Zhou Y, Lower EE, LI HP, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151 (01) 139-148
    CrossrefPubMedGoogle Scholar
  • 13 Nunes H, Humbert M, Capron F. , et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (01) 68-74
    CrossrefPubMedGoogle Scholar
  • 14 Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23 (11) 1216-1223
    CrossrefPubMedGoogle Scholar
  • 15 Corte TJ, Wells AU, Nicholson AG, Hansell DM, Wort SJ. Pulmonary hypertension in sarcoidosis: a review. Respirology 2011; 16 (01) 69-77
    PubMedGoogle Scholar
  • 16 Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134 (04) 809-811
    PubMedGoogle Scholar
  • 17 Tayal S, Voelkel NF, Rai PR, Cool CD. Sarcoidosis and pulmonary hypertension--a case report. Eur J Med Res 2006; 11 (05) 194-197
    PubMedGoogle Scholar
  • 18 Barst RJ, Ratner SJ. Sarcoidosis and reactive pulmonary hypertension. Arch Intern Med 1985; 145 (11) 2112-2114
    CrossrefPubMedGoogle Scholar
  • 19 Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120 (03) 866-872
    CrossrefPubMedGoogle Scholar
  • 20 Baughman RP, Culver DA, Cordova FC. , et al. Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPAH): a double blind, placebo controlled trial. Am J Respir Crit Care Med 2012; 185: A3639
    PubMedGoogle Scholar
  • 21 Vorselaars AD, Snijder RJ, Grutters JC. Increased number of pulmonary embolisms in sarcoidosis patients. Chest 2012; 141 (03) 826-827 , author reply 827
    CrossrefPubMedGoogle Scholar
  • 22 Swigris JJ, Olson AL, Huie TJ. , et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140 (05) 1261-1266
    CrossrefPubMedGoogle Scholar
  • 23 Crawshaw AP, Wotton CJ, Yeates DG, Goldacre MJ, Ho LP. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66 (05) 447-448
    CrossrefPubMedGoogle Scholar
  • 24 Ungprasert P, Crowson CS, Matteson EL. Association of sarcoidosis with increased risk of VTE: a population-based study, 1976 to 2013. Chest 2017; 151 (02) 425-430
    CrossrefPubMedGoogle Scholar
  • 25 Toonkel RL, Borczuk AC, Pearson GD, Horn EM, Thomashow BM. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration 2010; 79 (04) 341-345
    CrossrefPubMedGoogle Scholar
  • 26 Seferian A, Steriade A, Jaïs X. , et al. Pulmonary hypertension complicating fibrosing mediastinitis. Medicine (Baltimore) 2015; 94 (44) e1800
    CrossrefPubMedGoogle Scholar
  • 27 Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78 (06) 888-891
    CrossrefPubMedGoogle Scholar
  • 28 Hamilton-Craig CR, Slaughter R, McNeil K, Kermeen F, Walters DL. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ 2009; 18 (03) 222-225
    CrossrefPubMedGoogle Scholar
  • 29 Cremers J, Drent M, Driessen A. , et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol 2012; 24 (01) 17-24
    CrossrefPubMedGoogle Scholar
  • 30 Fetzer DT, Rees MA, Dasyam AK, Tublin ME. Hepatic sarcoidosis in patients presenting with liver dysfunction: imaging appearance, pathological correlation and disease evolution. Eur Radiol 2016; 26 (09) 3129-3137
    CrossrefPubMedGoogle Scholar
  • 31 Gupta S, Faughnan ME, Prud'homme GJ, Hwang DM, Munoz DG, Kopplin P. Sarcoidosis complicated by cirrhosis and hepatopulmonary syndrome. Can Respir J 2008; 15 (03) 124-126
    PubMedGoogle Scholar
  • 32 Salazar A, Mañá J, Sala J, Landoni BR, Manresa F. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994; 61 (02) 117-119
    CrossrefPubMedGoogle Scholar
  • 33 Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis 1988; 5 (01) 51-55
    PubMedGoogle Scholar
  • 34 Turner GA, Lower EE, Corser BC, Gunther KL, Baughman RP. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (01) 61-64
    PubMedGoogle Scholar
  • 35 Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128 (03) 1483-1489
    CrossrefPubMedGoogle Scholar
  • 36 Rapti A, Kouranos V, Gialafos E. , et al. Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung 2013; 191 (01) 61-67
    CrossrefPubMedGoogle Scholar
  • 37 Huitema MP, Spee M, Vorselaars VM. , et al. Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. Eur Respir J 2016; 47 (02) 673-676
    CrossrefPubMedGoogle Scholar
  • 38 Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48 (02) 516-522
    CrossrefPubMedGoogle Scholar
  • 39 Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (01) 207-213
    CrossrefPubMedGoogle Scholar
  • 40 Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med 2007; 13 (05) 439-444
    CrossrefPubMedGoogle Scholar
  • 41 Mirsaeidi M, Omar HR, Baughman R, Machado R, Sweiss N. The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (04) 317-320
    PubMedGoogle Scholar
  • 42 Alhamad EH, Shaik SA, Idrees MM, Alanezi MO, Isnani AC. Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med 2010; 10: 42
    CrossrefPubMedGoogle Scholar
  • 43 Baughman RP, Engel PJ, Nathan S. Pulmonary hypertension in sarcoidosis. Clin Chest Med 2015; 36 (04) 703-714
    PubMedGoogle Scholar
  • 44 Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015; 148 (04) 1055-1062
    CrossrefPubMedGoogle Scholar
  • 45 Handa T, Nagai S, Ueda S. , et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27 (01) 27-35
    PubMedGoogle Scholar
  • 46 Mirsaeidi M, Mortaz E, Omar HR, Camporesi EM, Sweiss N. Association of neutrophil to lymphocyte ratio and pulmonary hypertension in sarcoidosis patients. Tanaffos 2016; 15 (01) 44-47
    PubMedGoogle Scholar
  • 47 Singla S, Zhou T, Javaid K. , et al. Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis. Pulm Circ 2016; 6 (04) 465-471
    CrossrefPubMedGoogle Scholar
  • 48 Huitema MP, Grutters JC, Rensing BJ, Reesink HJ, Post MC. Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J 2016; 24 (06) 390-399
    CrossrefPubMedGoogle Scholar
  • 49 Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 1999; 14 (04) 270-278
    CrossrefPubMedGoogle Scholar
  • 50 Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (02) 108-116
    PubMedGoogle Scholar
  • 51 Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249 (03) 1042-1049
    CrossrefPubMedGoogle Scholar
  • 52 Arcasoy SM, Christie JD, Ferrari VA. , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (05) 735-740
    CrossrefPubMedGoogle Scholar
  • 53 Bertoli L, Rizzato G, Merlini R. , et al. Can pulmonary hypertension be predicted by non-invasive approach? Echocardiographic and haemodynamic study. Acta Cardiol 1984; 39 (02) 97-106
    PubMedGoogle Scholar
  • 54 Nathan SD, Shlobin OA, Barnett SD. , et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102 (09) 1305-1310
    CrossrefPubMedGoogle Scholar
  • 55 Baughman RP, Culver DA, Cordova FC. , et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145 (04) 810-817
    CrossrefPubMedGoogle Scholar
  • 56 Avouac J, Huscher D, Furst DE, Opitz CF, Distler O, Allanore Y. ; EPOSS group. Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis 2014; 73 (01) 191-197
    PubMedGoogle Scholar
  • 57 McLaughlin VV, Presberg KW, Doyle RL. , et al; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1, Suppl): 78S-92S
    CrossrefPubMedGoogle Scholar
  • 58 Appelbaum L, Yigla M, Bendayan D. , et al. Primary pulmonary hypertension in Israel: a national survey. Chest 2001; 119 (06) 1801-1806
    CrossrefPubMedGoogle Scholar
  • 59 Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124 (03) 922-928
    CrossrefPubMedGoogle Scholar
  • 60 Nardi A, Brillet PY, Letoumelin P. , et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38 (06) 1368-1373
    CrossrefPubMedGoogle Scholar
  • 61 Guyatt G, Gutterman D, Baumann MH. , et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006; 129 (01) 174-181
    CrossrefPubMedGoogle Scholar
  • 62 Liu L, Xu J, Zhang Y. , et al. Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension. Clin Respir J 2016 DOI: 10.1111/crj.12435
    CrossrefPubMedGoogle Scholar
  • 63 Condado JF, Babaliaros V, Henry TS, Kaebnick B, Kim D, Staton Jr GW. Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (03) 281-287
    PubMedGoogle Scholar
  • 64 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46 (04) 903-975
    CrossrefPubMedGoogle Scholar
  • 65 Pulido T, Adzerikho I, Channick RN. , et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 66 Ghofrani HA, Galiè N, Grimminger F. , et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369 (04) 330-340
    CrossrefPubMedGoogle Scholar
  • 67 Barnett CF, Bonura EJ, Nathan SD. , et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135 (06) 1455-1461
    CrossrefPubMedGoogle Scholar
  • 68 Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111 (02) 278-285
    CrossrefPubMedGoogle Scholar
  • 69 Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130 (05) 1481-1488
    CrossrefPubMedGoogle Scholar
  • 70 Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. J Heart Lung Transplant 2008; 27 (03) 329-334
    CrossrefPubMedGoogle Scholar
  • 71 Baughman RP, Judson MA, Lower EE. , et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (02) 110-120
    PubMedGoogle Scholar
  • 72 Ford HJ, Baughman RP, Aris R, Engel P, Donohue JF. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ 2016; 6 (04) 557-562
    CrossrefPubMedGoogle Scholar
  • 73 Judson MA, Highland KB, Kwon S. , et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (02) 139-145
    PubMedGoogle Scholar
  • 74 Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113 (01) 237-240
    CrossrefPubMedGoogle Scholar
  • 75 Hoeper MM, Schwarze M, Ehlerding S. , et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342 (25) 1866-1870
    CrossrefPubMedGoogle Scholar
  • 76 Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145 (06) 1321-1327
    CrossrefPubMedGoogle Scholar
  • 77 Condliffe R, Elliot CA, Hurdman J. , et al. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis 2014; 8 (03) 71-77
    CrossrefPubMedGoogle Scholar
  • 78 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
    CrossrefPubMedGoogle Scholar
  • 79 Rizzato G, Pezzano A, Sala G. , et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64 (02) 121-128
    PubMedGoogle Scholar
  • 80 Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. BMJ 1961; 2 (5261): 1165-1172
    CrossrefPubMedGoogle Scholar